Vector signs exclusive LyoGenesis deal with capacity of up to 800,000 vials a month
The July 7 agreement replaces Vector's May 13, 2026 investment option and ties its peptide platform to a Mequon cGMP manufacturing partner targeting gross margins of up to 60-80%.